Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event. About ...
Concurrent with Mr. Newton joining Keros’ Board of Directors, the Company also announced that Carl Gordon, Ph.D., CFA, will be stepping down as a director of the Company, effective March 9, 2026.
Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
Zacks Investment Research on MSN
Should investors buy, sell or hold KROS stock ahead of Q4 earnings?
We expect investors to focus on pipeline updates when Keros Therapeutics KROS reports fourth-quarter results shortly. The Zacks Consensus Estimate for sales and loss per share is pegged at $6.50 ...
CEO Jasbir Seehra outlined the company’s development priorities and partnership plans during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences conference, highlighting plans to init ...
In all patients, results of a platelet factor 4 (PF4)–induced platelet-activation (PIPA) assay were strongly positive, and serum from all the patients tested strongly positive against PF4 alone in a ...
A global research collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and Universitätsmedizin Greifswald (Germany) uncovered why a small number of people ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended ...
China’s National Medical Products Administration has approved Sino Biopharmaceutical Ltd.’s rovadicitinib, branded as Anxu, for first-line treatment of adults with intermediate- or high-risk primary ...
Mark Gurarie is a writer covering health topics, technology, music, books, and culture. He also teaches health science and research writing at George Washington University's School of Medical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results